Fox Run Management’s Outset Medical OM Stock Holding History

Fox Run Management’s Portfolio OM Stock Details OM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-791	Closed	-$218K	–	882
2023 Q1	$218K	Buy	+791	New	+$290K	0.07%	507

Other funds holding OM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fox Run Management's OM Position: Q2 2023 in Review

Fox Run Management sold out of Outset Medical (OM) in Q2 2023, closing a stake of 791 shares — an estimated $218K sold.

Fox Run Management first reported a position in OM in Q1 2023 and held it in 1 quarter. The position peaked at $218K in Q1 2023. 154 funds tracked by Wall St. Rank hold OM as of Q2 2023.

Fox Run Management reported no remaining Outset Medical position as of Q2 2023 after selling out during the quarter.
Fox Run Management sold 791 Outset Medical shares in Q2 2023, an estimated $218K.
Fox Run Management first reported a position in Outset Medical in Q1 2023 and held it in 1 quarter.
Fox Run Management's Outset Medical position peaked at $218K in Q1 2023.
154 funds tracked by Wall St. Rank held Outset Medical as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.